Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial + +... + Rianne L Seefat, MD MSca,* ∙ Sonja B Vliek, MDa,h,* ∙ Vincent M T de Jong, MD PhDa,* ∙ Sara Balduzzi, PhDb ∙ Ingrid A Mandjes, MScb ∙ Prof Valesca P Retèl, PhDd ∙ et al.

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial Rianne L Seefat, MD MSca,* ∙ Sonja B Vliek, MDa,h,* ∙ Vincent M T de Jong, MD PhDa,* ∙ Sara Balduzzi, PhDb ∙ Ingrid A Mandjes, MScb ∙ Prof Valesca P Retèl, PhDd ∙ et al. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00131-2/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-_EQY9zi-I1ZMEaSXDEbFawiyVWNDX-m0xL4QpTgFNcianRnZhR5wcaWMNP2oYXE5KTLrFtwIXXcdMlh-TH9b972hlOIw&_hsmi=428172142&utm_content=428106618&utm_source=hs_email Jul 2026 Volume 27Number 7p761-902, e317-e361 https://www.thelancet.com/journals/lanonc/issue/vol27no7/PIIS1470-2045(26)X2006-X Novel strategies to overcome the blood–brain barrier in triple-negative breast cancer brain metastases Yu Fan, PhD MDa ∙ Huiru Zhang, MBBSa ∙ Shan Tang, MBBSa ∙ Prof Masakazu Toi https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00146-4/abstract?utm_campaign=update-lanonc&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_lanonc&_hsenc=p2ANqtz-8PWVnyiWVbt4ZOZJ-BKLKNizjJDNjuQ8_JDntRE0YYy9kbCno0__upEGphueiDlTVzfMzyZgkyeoyti99V7dK3-h6afA&_hsmi=428172142&utm_content=428106618&utm_source=hs_email